Alexion Pharmaceuticals Inc.
352 Knotter Drive
Cheshire
Connecticut
06410
United States
Tel: 203-272-ALXN
Fax: 203-271-8198
Website: http://www.alexionpharma.com/
About Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
688 articles with Alexion Pharmaceuticals Inc.
-
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
8/27/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.
-
Alexion Receives Positive CHMP Opinion for SOLIRIS® (eculizumab) for the Treatment of NMOSD
7/26/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to extend the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive with a relapsing course of the disease
-
Alexion Reports Second Quarter 2019 Results
7/24/2019
Alexion Pharmaceuticals, Inc. announced financial results for the second quarter of 2019. Total revenues in the second quarter were $1,203.3 million, a 15 percent increase compared to the same period in 2018.
-
Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019
7/10/2019
Alexion Pharmaceuticals announced that the Company will report its financial results for the second quarter ended June 30, 2019 before the US financial markets open on July 24, 2019.
-
The U.S. Food and Drug Administration (FDA) gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adults that express a specific biomarker.
-
Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive
6/27/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.1
-
ADDING MULTIMEDIA Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive
6/27/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
-
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
-
U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
6/20/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA).
-
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
6/18/2019
Physicians in Japan will soon be able to prescribe a treatment for PNH that requires fewer infusions, reducing the treatment burden for patients
-
Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress
6/14/2019
ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition
-
Alexion to Present at the UBS Global Healthcare Conference
5/13/2019
Alexion Pharmaceuticals announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.m. ET.
-
Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
5/13/2019
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m. ET.
-
John Orloff and Brian Goff spoke with BioSpace about Alexion and new trends and developments the company is reporting.
-
New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
5/3/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the New England Journal of Medicine (NEJM) published positive data from the Phase 3 PREVENT study of SOLIRIS® (eculizumab), a first-in-class complement inhibitor, in adult patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD)
-
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
-
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
-
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
4/26/2019
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks.
-
Alexion Reports First Quarter 2019 Results
4/25/2019
1Q19 total revenues of $1,140.4 million, a 23 percent increase over 1Q18 and a 26 percent volume increase
-
Alexion to Report First Quarter Results on Thursday, April 25, 2019
4/12/2019
Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019.